Recently, Neo et al identified c-Rel as a positive regulator of EZH2 expression in activated primary murine lymphocytes and human malignant lymphoid cells and treatment with the c-Rel inhibitor pentoxifylline (PTX) not only reduced EZH2 expression but also reduced the survival of human leukemia/lymphoma cell lines by enhancing their sensitivity to the EZH2-specific inhibitor, GSK126 [123]. The gene discussed is REL; the disease is lymphoma.